TRSX's tedizolid cheaper than Pfizer's Zyvox...Seeking alpha article
"Trius can afford to price tedizolid at a whopping $320 a pill (4x Zyvox at its cheapest) and still undercut Pfizer in outpatient costs by up to a week. Nowhere on Earth is the saying "Time is money," more true than in a hospital. I doubt Trius will price tedizolid that high, but something tells me it's crossed the company's mind."
...and then there is always pot
I'm thinking this may end up like EXEL drug approval as investors find out that the market for these drugs will never be highly profitable for these companies.
Perhaps we are fools for using our money to fund this research for so many years with such a small payoff.
There is no comparison. EXEL is so large that tiny sales will not move it much. TSRX relatively tiny, with much lower share count. TSRX will be way up from here if Ted is approved. Probably would be bought out by some larger company hurting for new products and sales. Buying below $5 is nice!!
EXEL is $325mil in debt and has to dilute heavily in order to raise more funds to follow through with their drug. TRSX, in a much better financial position with the Bayer deal although it limit's future profits. Haven't read particulars behind the exact deal but it could still be a windfall for both companies. especially if they merge.